From Wikipedia, the free encyclopedia
Jump to: navigation, search
Halometasone cream.jpg
Clinical data
Trade names Sicorten
AHFS/Drugs.com International Drug Names
Routes of
ATC code
Synonyms (6S,8S,9R,10S,11S,13S,16R,17R)-2-chloro-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxy-acetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
ECHA InfoCard 100.051.496
Chemical and physical data
Formula C22H27ClF2O5
Molar mass 444.896 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Halometasone is a potent (Group III) synthetic tri-halogenated corticosteroid for topical application possessing pronounced anti-inflammatory, antiexudative, antiepidermoplastic, antiallergic, and antipruritic properties. It has been approved in many European countries including Spain, Germany, Switzerland, Austria, Netherlands, Belgium, and Portugal and other countries such as China, Hong Kong, Turkey, Israel, South Africa and India.

It has been used to treat chronic psoriasis vulgaris[1] and non-infected acute eczematous dermatoses (eczema).[2] One study demonstrated that 0.05% halometasone cream was more effective than 0.05% betamethasone cream in treating dermatitis, though both were well-tolerated with no systemic adverse effects reported.[3]


  1. ^ Galbiati, G; Bonfacini, V; Candiani, F (1983). "Halometasone cream by day and halometasone ointment at night for the treatment of patients with chronic psoriasis vulgaris". The Journal of International Medical Research. 11 Suppl 1: 31–3. PMID 6339290. 
  2. ^ Yawalkar, SJ; MacArol, V; Montanari, C (1983). "An overview of international clinical trials with halometasone cream". The Journal of International Medical Research. 11 Suppl 1: 1–7. PMID 6339286. 
  3. ^ Schuppli, R; Dressler, H; Yawalkar, SJ; Weirich, EG (1983). "Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate". Zeitschrift für Hautkrankheiten. 58 (4): 230–7. PMID 6342285.